The DOI matches its Crossref record.
Renal safety of tenofovir in HIV treatment-experienced patients
Abstract
The safety of tenofovir disoproxil fumarate (TDF) was assessed in two double-blind, placebo-controlled studies. Furthermore, we retrospectively collected 19 cases of TDF-associated tubular dysfunction. The incidence of renal events was similar among the active TDF groups and the placebo group in the two double-blind, placebo-controlled studies. Proximal tubulopathy was diagnosed 6.89±5.51 months after TDF therapy started. All abnormalities normalized within 4.7±2.94 weeks after drug discontinuation. The renal parameters are reported in antiretroviral treatment-experienced patients included in two randomized double-blind, placebo-controlled studies of tenofovir disoproxil fumarate (TDF) in the treatment of HIV-1 infection. Furthermore, we retrospectively collected and analysed 19 cases of TDF-associated tubular dysfunction. In study 902, 189 patients were randomly assigned to receive TDF or placebo: group 1 received TDF 75 mg/day, group 2 received TDF 150 mg/day, group 3 received TDF 300 mg/day, and group 4 received placebo for 48 weeks. The mean and median values for serum creatinine remained constant for the four groups over the treatment period. All abnormalities were grade 1 in severity (0.5 mg/dl change from baseline). Over 48 weeks, the incidence of grade 1 elevations of serum creatinine levels was 6, 4 and 2% for the 75, 150 and 300 mg TDF groups, respectively. No patient discontinued treatment as a result of serum creatinine level elevations. There were no marked changes from baseline in the median phosphorus levels in the three TDF groups. At week 48, the incidence of grades 1 or 2 hypophosphataemia was similar to that seen at week 24 (17, 14 and 24%) for the 75, 150 and 300 mg TDF groups, respectively. In study 903, 552 patients were blindly randomly assigned to receive TDF 300 mg/day (368) or placebo (184) with their existing regimen. Twenty-four weeks after randomization, patients receiving placebo were blindly crossed over to TDF 300 mg/day for the remainder of the 48-week study. The mean values for serum creatinine remained constant over the treatment period and the incidence of elevation in serum creatinine levels was similar between the TDF (2%) and placebo (1%) groups. All abnormalities were grade 1 and remained in the normal range i.e. less than 1.5 mg/dl (133 μmol/l). No patients discontinued treatment as a result of serum creatinine level elevations. There were no marked changes in the mean and median serum phosphorus levels over the treatment period in all groups. Furthermore, grades 1 or 2 hypophosphataemia occurred in 12 and 7% of TDF and placebo-treated patients, respectively (P > 0.05). No patients discontinued treatment as a result of hypophosphataemia. Proteinuria assessed using the dipstick test was not significantly different in the four groups of study 902. In addition, the 3+ urine glucose frequency was similar in all groups (3%). Over the past 2 years, we collected data on 19 patients with tubular dysfunction: 13 men and six women (mean age 42.8 ± 9.8 years, mean HIV infection duration 12.8 ± 4 years). Four patients for which creatinine clearance was determined at baseline had renal insufficiency (from 32 to 78 ml/min). Tubular dysfunction or renal failure (a rise in the serum creatinine level of > 25%) was diagnosed 6.89 ± 5.51 months after starting TDF. All abnormalities normalized within 4.7 ± 2.9 weeks after drug discontinuation. One patient experienced tubular dysfunction when TDF was reintroduced. Symptoms resolved within a week after TDF withdrawal. Nephrogenic diabetes insipidus occurred in three cases and renal failure occurred in 14 out of the 19 cases. The mean serum creatinine level before TDF was 0.88 ± 0.24 mg/dl and the mean creatinine level after the increase was 2.64 ± 2.08 mg/dl. The mean serum creatinine level after recovery was 1.26 ± 0.44 mg/dl. TDF was withdrawn in 13 of the 14 patients and renal function improved in all cases. No patient died. In five patients, all antiretroviral agents except TDF were reintroduced after a while, with no increase in the serum creatinine level. All patients had at least one proximal tubular dysfunction abnormality in which this parameter was studied as assessed with normoglycemic glycosuria (100%), mild proteinuria (100%), hypophosphoremia (100%), metabolic acidosis with normal anion gap (53%), or hypokalemia (53%). Hypouricemia and aminoaciduria, which were not routinely performed tests, were found in five and two patients, respectively. Three antiretroviral drugs were frequently combined with TDF: lamivudine (47%), lopinavir (59%), and ritonavir (53%). Lopinavir and ritonavir were combined in six patients (31.5%). Kidney biopsy was obtained from five out of 19 patients. Microscopic examination revealed severe acute tubular necrosis associated with marked interstitial fibro-oedema. The distal and proximal renal tubules were both affected, with confluent necrosis of the proximal tubule epithelium and a dramatic vacuolizat
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Acyclic nucleoside phosphonates: a key class of antiviral drugs
Clercq, E. D., & Holý, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1877 · Cited by 688
Worm, S. W., Sabin, C., Weber, R., Reiss, P., El‐Sadr, W., Dabis, F., De Wit, S., Law, M., Monforte, A. D., Friis‐Møller, N., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/649897 · Cited by 648
Management of hepatitis B: Summary of a clinical research workshop†
Hoofnagle, J. H., Doo, E., Liang, T. J., Fleischer, R., & Lok, A. S. F. (2007) · Hepatology · doi:10.1002/hep.21627 · Cited by 628
Gupta, S. K., Eustace, J. A., Winston, J. A., Boydstun, I. I., Ahuja, T. S., Rodriguez, R. A., Tashima, K. T., Roland, M., Franceschini, N., Palella, F. J., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/430257 · Cited by 581
Cooper, R. D., Wiebe, N., Smith, N., Keiser, P., Naicker, S., & Tonelli, M. (2010) · Clinical Infectious Diseases · doi:10.1086/655681 · Cited by 565
Metadata
- Authors
- Izzedine, H., Isnard-Bagnis, C., Hulot, J. S., Vittecoq, D., Cheng, A., Jais, C. K., Launay-Vacher, V., & Deray, G.
- Venue
- AIDS
- Published
- 2004-04
- Volume
- 18
- Issue
- 7
- Pages
- 1074-1076
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W1987818325
- Cited by
- 173
- References
- 0
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renal safety of tenofovir in HIV treatment-experienced patients. https://app.cochat.ai/papers/10.1097/00002030-200404300-00019
- The paper
- Izzedine, H., Isnard-Bagnis, C., Hulot, J. S., Vittecoq, D., Cheng, A., Jais, C. K., Launay-Vacher, V., & Deray, G. (2004). Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. https://doi.org/10.1097/00002030-200404300-00019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.